Image source: Shutterstock
Highlights
- ImpediMed's SOZO-Core business revenue increased by 14% in FY24.
- In FY24, total revenue dropped by 9% due to the cessation of the AstraZeneca trial.
- The company aims to reduce cash expenditure by 10% in FY25.
ImpediMed Limited (ASX:IPD) is an ASX-listed medical software technology company that utilises bioimpedance spectroscopy (BIS) for non-invasive measurement and monitoring of fluid status and tissue composition. On 8 October 2024, the company notified that the US National Accreditation Program for Breast Centres has updated its standards to include BIS.
IPD is the only company that provides FDA-cleared BIS technology for clinically assessing lymphoedema. The SOZO technology of IPD is well recognised and accepted for its accuracy and effectiveness in screening for lymphoedema.
During the financial year 2024 (FY24), revenue from SOZO-Core business increased by 14% YoY to AUD 9.7 million, while total revenue dropped by 9% YoY to AUD 10.3 million. Group revenue fell in FY24 due to cessation of the AstraZeneca trial.
The period also recorded fall in operating loss before tax to AUD 19.8 million from AUD 20.5 million. During the reported period, the company conducted restructuring, cost cutting and reallocation of resources to customer-facing roles.
IPD Outlook
The focus is on supporting clinicians in achieving top-tier guideline-driven care to prevent breast care-related lymphoedema (BCRL), establishing SOZO as a vital investment in patient outcomes.
Moreover, the company is committed to boosting sales and improving cost efficiency. In FY25, cash expenditure anticipated to decrease 10% compared to FY24.
In 1HFY25, the company plans to participate in 14 conferences in the US to increase awareness of SOZO among a broader range of stakeholders involved in BCRP prevention.
Share performance of IPD
IPD shares closed 1.69% lower at AUD 0.058 apiece on 9 October 2024. In the past one year, IPD’s share price has declined by almost 61.33%, while, in the past one month, it has increased by 26.09%.
52-week high of IPD is AUD 0.16, recorded on 10 January 2024, and 52-week low is AUD 0.042, recorded on 11 September 2024.

IPD Daily Technical Chart, Source: REFINITIV
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 09 October 2024. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer:
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.